Welcome to our dedicated page for Oruka Therapeutics SEC filings (Ticker: ORKA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Oruka Therapeutics, Inc. (NASDAQ: ORKA) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including current reports, financial statements, and material agreements. As a Nasdaq-listed clinical-stage biotechnology company focused on biologic therapies for chronic skin diseases, Oruka uses its SEC filings to report key corporate, financial, and governance information related to its psoriasis and inflammatory disease programs.
Investors can review Form 8-K current reports where Oruka describes material events such as private placement financings, changes in directors and executive officers, and the terms of securities purchase agreements and registration rights agreements. These filings also document board appointments, committee roles, director compensation, and equity awards, providing detail on corporate governance and leadership transitions.
Periodic reports such as Form 10-Q and Form 10-K (when available) contain condensed consolidated financial statements, including research and development and general and administrative expenses, net losses, cash, cash equivalents, and marketable securities. For a clinical-stage company like Oruka, these filings help readers understand the level of investment in plaque psoriasis and other dermatologic programs, as well as the company’s capital position and runway assumptions.
Stock Titan enhances these filings with AI-powered summaries that highlight the most important points, such as trial-related disclosures, financing structures, and changes in share count. Users can also access information related to equity issuances and warrant terms, and track how Oruka’s capital structure evolves over time. Real-time updates from EDGAR ensure that new ORKA filings, including any future proxy statements or insider transaction reports on Form 4, appear promptly with plain-language explanations to support more efficient review.
BALL KRISTINE M reported acquisition or exercise transactions in this Form 4 filing.
Oruka Therapeutics director Kristine M. Ball received a grant of stock options covering 9,136 shares of common stock at 55.23 per share. The options vest in 12 equal monthly installments beginning on June 2, 2026 and expire on June 1, 2036. Following this award, she holds options for 9,136 shares directly.
Oruka Therapeutics, Inc. reported that investment vehicles managed by Fairmount Funds Management received a new stock option grant linked to its common stock. The option covers 9,136 shares with an exercise price of $55.23 per share and expires on June 1, 2036.
The option vests in equal monthly installments of 1/12 starting on June 2, 2026, contingent on continued service to Oruka Therapeutics. The filing explains that Peter Harwin holds the option for one or more Fairmount-managed funds and must deliver any net cash or stock from the option to Fairmount for those funds’ benefit.
Fairmount, Harwin, and Tomas Kiselak each disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest. The transaction is characterized as a grant or award acquisition of a derivative security, rather than an open-market trade.
Oruka Therapeutics, Inc. entered into a First Amendment to its IL-23 License Agreement with Paragon Therapeutics, Inc. This amendment broadens Oruka’s licensed field to cover all therapeutic, prophylactic, palliative and diagnostic uses of the IL‑23 program, including inflammatory bowel disease, subject to timing limits on when dosing may begin.
Under the amendment, Oruka may not dose a human patient in a clinical trial of ORKA‑001 for inflammatory bowel disease in a combination regimen until June 1, 2028, or as a monotherapy until June 1, 2030. If Oruka or a Paragon licensee completes a material transaction such as a change of control, any remaining restrictions outside the original field will continue only until June 1, 2028 and then terminate.
Oruka Therapeutics director Carl Dambkowski reported a mix of stock sales and option exercises in Oruka Therapeutics, Inc. common stock. On May 21, 2026, he sold a total of 105,000 shares in open‑market transactions at weighted average prices around $58–$60 per share under a pre‑arranged Rule 10b5‑1 trading plan. On the same date, he exercised stock options and warrants covering 62,260 shares at exercise prices of $6.84, $7.80, and $11.77 per share, converting derivative awards into common stock. He continues to hold unexercised options and warrants that expire between 2034 and 2035.
ORKA-related securities holder submitted a Form 144 proposing sales of common stock totaling 105,000 shares. The filing lists two transactions: 62,260 shares tied to an Exercise of Stock Options dated 05/21/2026 and 42,740 shares from a Partnership Distribution dated 02/14/2024. The sales are described as cash transactions.
Oruka Therapeutics, Inc. Senior Vice President, Finance Arjun Agarwal reported a mix of stock option exercises and share sales in Oruka common stock. On May 18, 2026, he exercised 7,833 employee stock options at exercise prices of $34.39 and $12.50 per share, converting derivative awards into common shares. The same day, he sold 10,290 common shares in open-market transactions under a pre-arranged Rule 10b5-1 trading plan, at weighted average prices spanning approximately $57.72 to $61.76 per share. This pattern reflects routine option exercise paired with partial share sales for liquidity under a pre-planned program.
ORKA reported proposed sales of common stock by insiders under multiple mechanisms. The notice lists 19,749 shares from an exercise of stock options dated 05/18/2026, 1,758 shares from the Employee Stock Purchase Plan dated 12/08/2025, and 699 shares issuable upon Restricted Stock Units dated 03/14/2026.
The filing also records a prior sale of 395 shares by Arjun Agarwal on 03/16/2026 for $16,313.50.
Oruka Therapeutics, Inc.’s Chief Medical Officer, Joana Goncalves, reported option exercises and related share sales. On May 15, 2026, she exercised options and warrants to acquire a total of 7,000 shares of common stock at exercise prices of $7.80 and $6.84 per share. On the same date, she sold an aggregate 7,000 common shares in open-market transactions at weighted-average prices of about $61.56, $62.42 and $63.52 per share pursuant to a Rule 10b5-1 trading plan entered into on September 19, 2025. Following these transactions, she directly owned 33,377 shares of Oruka Therapeutics common stock.
Oruka Therapeutics, Inc. Schedule 13G/A Amendment No. 1 reports that Viking Global Investors and affiliated entities beneficially own 2,666,690 shares of Common Stock, representing 5.3% of the class, effective March 31, 2026. The filing removes David C. Ott as a reporting person due to his retirement.
The filing states the 2,666,690 shares comprise 1,600,014 shares held by Viking Global Opportunities entities and 1,066,676 shares held by Viking Global Opportunities Drawdown entities. Shares outstanding are listed as 50,167,623 as of March 31, 2026.
Oruka Therapeutics, Inc. reported a net loss of $31.8 million for the three months ended March 31, 2026, reflecting increased investment in its psoriasis and inflammatory disease pipeline. Research and development expenses rose to $29.1 million and general and administrative expenses to $7.3 million, driven by higher clinical activity, headcount and stock-based compensation.
The company held $496.0 million in cash, cash equivalents and marketable securities as of March 31, 2026 and later strengthened liquidity with $38.9 million of at-the-market share sales and a subsequent underwritten offering raising gross proceeds of $700.4 million. Lead antibodies ORKA-001 and ORKA-002 advanced through Phase 1 and Phase 2 studies, with ORKA-001 showing high rates of complete skin clearance in psoriasis and ORKA-002 moving into mid-stage trials in psoriasis and planned trials in hidradenitis suppurativa.